gip/glp-1 drugs Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care The Effects of Dual GLP-1/GIP

[DOI] [PubMed] [Google Scholar] 8.Hall S, Isaacs D, Clements JN

This is a clever claim because it sidesteps the regulatory issues around selling actual GLP-1 (which would require a prescription)

FDA Approves Ozempic (Semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults With Type 2 Diabetes and Chronic Kidney Disease

Regarding the treatment of obesity, we expect SMG to be approved by more countries FDA in the future

Nonetheless, their impact on appetite can be profound, occasionally leading to the development or exacerbation of restrictive eating behaviors